Live Breaking News & Updates on Michele Reni

Stay updated with breaking news from Michele reni. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Chemo-Free Maintenance Combo Promising in Pancreatic Cancer

Niraparib-ipilimumab combination yields 6-month progression-free survival rate of 60% ....

University Of Pennsylvania , United States , Kima Reiss , Michele Reni , Mike Bassett , Giulia Orsi , San Raffaele Scientific Institute , Vitae Salute University , Perelman School Of Medicine , Perelman School , Salute University ,

Merus N.V.: Merus Announces Collaborations in Israel, Italy and Spain to Increase Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awareness of the Phase 1/2 eNRGy Clinical Trial

Merus N.V.: Merus Announces Collaborations in Israel, Italy and Spain to Increase Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awareness of the Phase 1/2 eNRGy Clinical Trial
and Triclonics
), today announced new collaborations in Israel, Italy and Spain to expand molecular screening opportunities for patients with cancers that may have neuregulin 1 (NRG1) fusions and to raise awareness of the Merus eNRGy clinical trial of its bispecific antibody zenocutuzumab (Zeno). In the collaborations, Merus plans to support molecular screenings for eligible patients with pancreatic adenocarcinoma in Israel and Italy, and with non-small cell lung cancer (NSCLC) in Spain, aimed to identify the presence of NRG1 fusions. Each collaborating organization in turn has agreed as follows: ....

United States , United Kingdom , Andrew Joe , Michele Reni , Exchange Commission , San Raffaele Scientific Institute , Italian Association For The Study Of Pancreas , Progenetics Ltd , Principal Investigator , Universidad De Navarra , Chief Medical Officer , North America , Private Securities Litigation Reform Act , Quarterly Report , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , ஆண்ட்ரூ ஓஹோ , பரிமாற்றம் தரகு , சான் ராப்பஆேழே அறிவியல் நிறுவனம் , ப்ரிந்ஸிபல் புலனாய்வாளர் , யுனிவர்சிடாட் டி நாவார , தலைமை மருத்துவ அதிகாரி , வடக்கு அமெரிக்கா , ப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம் , காலாண்டு அறிக்கை ,

Merus Announces Collaborations in Israel, Italy and Spain to Increase Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awareness of the Phase 1/2 eNRGy Clinical Trial

Published: May 13, 2021
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics
® and Triclonics
®), today announced new collaborations in Israel, Italy and Spain to expand molecular screening opportunities for patients with cancers that may have neuregulin 1 (NRG1) fusions and to raise awareness of the Merus eNRGy clinical trial of its bispecific antibody zenocutuzumab (Zeno). In the collaborations, Merus plans to support molecular screenings for eligible patients with pancreatic adenocarcinoma in Israel and Italy, and with non-small cell lung cancer (NSCLC) in Spain, aimed to identify the presence of NRG1 fusions. Each collaborating organization in turn has agreed as follows: ....

United States , United Kingdom , Zenocutuzumab Zeno , Andrew Joe , Michele Reni , Kathleen Farren , Exchange Commission , San Raffaele Scientific Institute , Communications Specialist , Italian Association For The Study Of Pancreas , Principal Investigator , Universidad De Navarra , Chief Medical Officer , North America , Merus Dock , Zeno Dock , Private Securities Litigation Reform Act , Quarterly Report , Media Inquiries , Erus Announces Collaborations In Israel , Taly And Spain To Increase Screening Identification Of Cancer Patients With Nrg1 Fusion Tumors Raise Awareness The Phase 1 2 Enrgy Clinical Trial , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , ஆண்ட்ரூ ஓஹோ , க்யாத்லீந் ஃப்யாரந் , பரிமாற்றம் தரகு ,